Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ulixertinib + Nab-paclitaxel + Gemcitabine in Metastatic Pancreatic Cancer
NCT02608229Phase 1Terminated
- Sponsor
- Washington University School of Medicine
- Start
- Jun 2016
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ulixertinib (2 arms), sponsored by Washington University School of Medicine. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Jun 2016; status: terminated.
02
Drugs
ulixertinib
Beyond the preview
Go deeper on NCT02608229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02608229.